Arkolith/Insider Trading/SNDX/Form 4

Metzger Michael A

Chief Executive Officer, DirectorSyndax Pharmaceuticals Inc (SNDX) · full profile →Form 4 · filed Feb 7, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 5, 2025Grant(A)89K—$0313K
Feb 5, 2025Grant(A)61K—$0224K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 5, 2025Grant(A)364K$14.65$5.3M364K

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-25-016384) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML